Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis (PRIVIG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00220779
Recruitment Status : Completed
First Posted : September 22, 2005
Results First Posted : April 11, 2014
Last Update Posted : April 27, 2016
Information provided by (Responsible Party):
Grifols Therapeutics LLC

September 13, 2005
September 22, 2005
September 24, 2009
April 11, 2014
April 27, 2016
December 2002
February 2005   (Final data collection date for primary outcome measure)
Percentage of Relapse Free Subjects (no Relapse) [ Time Frame: 12 months ]
A relapse was defined for the purposes of this study as the appearance or reappearance of one or more neurological symptoms or worsening of an old symptom attributed to multiple sclerosis (MS) persisting for at least 48 hours and immediately preceded by a relatively stable or improving neurological state of at least 30 days.
Evaluate two dose regimens of IGIV-C 10% compared to placebo on the number of patients with Relapsing – Remitting Multiple Sclerosis (RRMS) who remain relapse free during a 1 year treatment period.
Complete list of historical versions of study NCT00220779 on Archive Site
Effect on the Combined Unique Lesion Activity on Magnetic Resonance Imaging (MRI) [ Time Frame: 1 year ]
The secondary objective is to evaluate the effect on the combined unique lesion activity on magnetic resonance imaging (MRI.)
Not Provided
Not Provided
Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis
Randomized, Double-Blind, Placebo-Controlled Study to Compare the Effects of Different Dose Regimens of IGIV Chromatography (IGIV-C), 10% Treatment on Relapses in Patients With Relapsing Remitting Multiple Sclerosis
The trial will study 2 doses of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) for the number of relapses that occur in a 1 year treatment period.

This trial is designed as a multi-national, randomized, double-blind, placebo-controlled prospective trial with three parallel groups.

One hundred twenty (120) patients, 40 per treatment arm, with relapsing-remitting (RR) multiple sclerosis will be enrolled in this trial. Eligible patients must have a diagnosis of MS as per the McDonald Criteria. In addition, patients must have a diagnosis of relapsing-remitting course of MS defined as periods of worsening of neurological function with full recovery or with sequelae and residual deficit upon recovery; periods between disease relapses characterized by lack of disease progression. Patients must also have active disease with at least 1 defined documented relapse in the last year.

During a 2 month run-in period, 2 MRIs will be performed 6 weeks apart and patients will be stratified based on the presence or absence of 1 or more Gadolinium enhancing lesions on the first MRI (Gd-enhancing lesion yes-no) and will be randomized to one of two dose regimens of IGIV-C or matching placebo. Patients will receive study drug infusions every 4 weeks for 48 weeks for a total of 12 infusions. Patients will be evaluated by MRI every 6 weeks and by clinical assessments every 3 months. A follow-up visit will occur 4 weeks after the last infusion.

The treatment groups are as follows:

  • IGIV-C - 0.2 g/kg body weight (bw)/infusion (2 ml/kg bw)
  • IGIV-C - 0.4 g/kg bw/infusion (4 ml/kg bw)
  • placebo (0.1% albumin) - 4 ml/kg bw/infusion

For blinding purposes, at each infusion, all patients will receive a total volume of 4 ml/kg bw. For patients receiving 0.2 g/kg bw of IGIV-C, the final volume of 4 ml/kg bw will be adjusted by the addition of dextrose 5%. Placebo will be supplied as Albumin 5% or Albumin 25% and diluted with either dextrose 5% or saline to a final concentration of 0.1% albumin.

Dose adaptation will be performed for subsequent infusions in case the patient's body weight has changed > 10%. The maximum amount available per infusion will be 400 ml (8 vials) calculated for a patient with a body weight of 100 kg. The suggested initial infusion rate will be 0.02 ml/kg/min for the first 15 minutes. If there is no evidence of a hypersensitivity reaction, the infusion may be given at a slowly increasing rate over the next 30 minutes up to a maximum allowable rate of 0.08 ml/kg/min. As such, the infusion for a 70 kg patient will take approximately 1hour 15 min. The overall infusion time may have a range from 1 to 2 hours.

Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Multiple Sclerosis, Relapsing-Remitting
  • Drug: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
    Other Names:
    • Gamunex®
    • IGIVnex®
    • Gaminex
    • IGIV-C
    • Immune Globulin Intravenous (Human) , 10%
    • IGIV
    • BAY 41-1000
    • TAL-05-00004
    • IGIV-C, 10%
    • IVIG
    • Immune Globulin (Human), 10% (IGIV)
    • Immune Globulin Intravenous, 10% by Chromatography Process
    • NDC 13533-645-12
    • NDC 13533-645-15
    • NDC 13533-645-20
    • NDC 13533-645-24
    • NDC 13533-645-71
  • Drug: Albumin (Human) 25%, United States Pharmacopeia (USP)
    Other Names:
    • Plasbumin®-5
    • Plasbumin®-25
    • Plasbumin®-5 (Low Aluminum)
    • Plasbumin®-25 (Low Aluminum)
    • Albumin (Human) 5%, USP
    • Albumin (Human) 25%, USP
    • TAL-05-00009
    • TAL-05-00023
    • TAL-05-00025
    • TAL-05-00026
    • BAY 34-9255
    • NDC 13533-684-16
    • NDC 13533-684-25
    • NDC 13533-684-71
    • NDC 13533-685-20
    • NDC 13533-685-25
    • NDC 13533-685-27
    • NDC 13533-690-20
    • NDC 13533-690-25
    • NDC 13533-690-27
    • NDC 13533-692-16
    • NDC 13533-692-20
    • NDC 13533-692-71
  • Experimental: Group 1
    IGIV-C 0.2 g/kg bw/infusion (2 ml/kg bw)
    Intervention: Drug: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
  • Experimental: Group 2
    IGIV-C 0.4 g/kg bw/infusion (4 ml/kg bw)
    Intervention: Drug: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
  • Placebo Comparator: Group 3
    placebo (0.1% albumin) 4 ml/kg bw/infusion
    Intervention: Drug: Albumin (Human) 25%, United States Pharmacopeia (USP)
Fazekas F, Lublin FD, Li D, Freedman MS, Hartung HP, Rieckmann P, Sørensen PS, Maas-Enriquez M, Sommerauer B, Hanna K; PRIVIG Study Group; UBC MS/MRI Research Group. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology. 2008 Jul 22;71(4):265-71. doi: 10.1212/01.wnl.0000318281.98220.6f.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
February 2005
February 2005   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Symptoms consistent with Multiple Sclerosis up to 5 years
  • Diagnosis of multiple sclerosis according to McDonald criteria.
  • Diagnosis of relapsing-remitting (RR) multiple sclerosis (MS) (Defined as periods of worsening of neurological function with full recovery or with sequelae and residual deficit upon recovery; periods between disease relapses characterized by lack of disease progression
  • Kurtzke Extended Disability Status Scale (EDSS) < 5.0
  • At least 1 defined and documented relapse during the last year. Prior relapses where symptoms were due solely to a change in Bowel/Bladder Function or Cognitive Function will not be considered relapses as defined by this protocol and therefore not counted for inclusion into the study.
  • Females or males; females of childbearing potential must use adequate contraception
  • Clinically stable for at least 30 days prior to entry
  • At least 9 hyperintense T2 lesions on MRI or 1 Gd-enhancing lesion according to McDonald/Barkhof dissemination-in-space criteria at entry
  • Patients who have been informed about available treatments and decided, not to go on these treatments
  • Written informed consent obtained prior to the initiation of any study related procedures

Exclusion Criteria:

  • Females who are pregnant, breast feeding, or if, of childbearing potential, unwilling to practice adequate contraception throughout the study
  • Prior therapy with azathioprine or any immunosuppressant agents within 6 months prior to study entry
  • Prior steroid, methylprednisolone or adrenocorticotropic hormone (ACTH) therapy within 30 days prior to study entry
  • Therapy with interferons (Betaseron®, Avonex®, Rebif®), glatiramer acetate (Copaxone®) or IGIV within 3 months prior to study entry or during the study
  • Use of an investigational compound within 6 months prior to study entry
  • Previous lymphoid irradiation or prior to treatment with cyclophosphamide, methotrexate or mitoxantrone
  • Cardiac insufficiency (NYHA III/IV), cardiomyopathy, significant cardiac dysrhythmia requiring treatment, unstable or advanced ischemic heart disease (CCS III or IV), or malignant hypertension
  • History of renal insufficiency or serum creatinine levels greater than 2.5 mg/dL (221 µmol/L)
  • Known selective immunoglobulin A (IgA) deficiency or known antibodies to IgA
  • Conditions whose symptoms and effects could alter protein catabolism and/or immunoglobulin G (IgG) utilization (e.g., protein-losing enteropathies, nephrotic syndrome)
  • Any medical, psychiatric or other circumstances which impede or restrict the patient's participation in the study or any contraindication to contrast enhanced MRI (e.g.,pacemaker, aortic clip or any metal implant)
  • Patients with clinically significant medical conditions including, but not limited to cardiac, pulmonary, hepatic, hematological (e.g. known coagulation disorder, history of deep venous thrombosis and/or pulmonary embolism), endocrine,or renal dysfunction, autoimmune disorders, severe environmental allergies or chronic infections
Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Austria,   Canada,   Czech Republic,   Germany,   Greece,   Hungary,   Israel,   Poland,   Slovakia,   Sweden,   United Kingdom,   United States
Not Provided
Not Provided
Grifols Therapeutics LLC
Grifols Therapeutics LLC
Not Provided
Principal Investigator: Fred D Lublin, MD Mt Sinai Medical Center, New York, NY
Grifols Therapeutics LLC
March 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP